9805733-4
LPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/48, 9/20, 47/10, 31/495

A3

(11) International Publication Number: WO 98/07429

(43) International Publication Date: 26 February 1998 (26.02.98)

(21) International Application Number: PCT/US97/19388

(22) International Filing Date: 21 May 1997 (21.05.97)

(30) Priority Data:
08/655,329 24 May 1996 (24.05.96) US

(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(72) Inventors: SANGEKAR, Surendra, A.; 127 Sinclair Avenue, Union, NJ 07083 (US). VADINO, Winston, A.; 9 Glenmont Road, Whitehouse Station, NJ 08889 (US). LEE, Ping, I.; 312 Pine Tree Road, Radnor, PA 19087 (US).

(74) Agents: MAJKA, Joseph, T. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
23 April 1998 (23.04.98)

(54) Title: ANTIFUNGAL COMPOSITION WITH ENHANCED BIOAVAILABILITY

(57) Abstract

A pharmaceutical composition comprising: i) an antifungal agent which is (-)-(2R-cis)-4-[4-[4-[4-[[-5-(2,4-difluorophenyl)-tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxypropyl]-3H-1,2,4-triazol-3-one; ii) at least one non-ionic surfactant; and iii) a diluent. The composition enables the antifungal compound, which has very low water solubility, to have enhanced bioavailability in mammals, such as humans.